• Ethris, Neurimmune work on inhalable COVID-19 therapy pharmatimes
    April 02, 2020
    Joining the fight against COVID-19, Ethris GmbH and Neurimmune AG have announced an exclusive partnership to develop an mRNA-based anti-SARS-CoV-2 antibody therapeutic as an inhalable COVID-19 treatment.
PharmaSources Customer Service